Table 1 : Summary of current therapies in mRCC.


  1st Line 2nd Line  Pipeline

Multi targeting TKIs Sunitinib
Sorafenib
Pazopanib
Axitinib
Sorafenib
Sunitinib
Pazopanib
Cabozantinib (NCT01835158NCT01865747)
Dovitinib (NCT01223027)
Lenvatinib (NCT01136733)
--

VEGF receptor antibody Bevacizumab with IFN-α Bevacizumab --

mTOR inhibitor Temsirolimus Everolimus
Temsirolimus
--
--

Immunotherapy HD-IL2 HD-IL2 Nivolumab (NCT01472081; NCT02210117)
Ipilimumab (NCT00057889, NCT01472081)
IMP321 (NCT00351949)
IMA901 (NCT01265901)
AGS-003 (NCT01582672)
WX-G250 (NCT01826877)

Iris Zhi et al.Journal of Cancer Therapeutics and Research  2014 3:8DOI : 10.7243/2049-7962-3-8